EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE

What we do

Subscribe to
our newsletter!

AGM 2019 Agenda

Find below the final agenda for the MPE Annual General Meeting 2019.

Friday, 15 March 2019

13:00 – 15:00	Check-in and registration Lunch at the hotel restaurant “Bistro”
15:00 – 15:10	Welcome & Introductions Hans Scheurer – President MPE Ananda Plate – CEO MPE
15:10 – 16.10	Myeloma Treatment Updates Chair: Riikka-Leena Manninen, MPE Board Member Treatment of newly diagnosed myeloma Role of maintenance treatment New and upcoming treatments for NDMM Updates on treatment of relapsed myeloma New and upcoming treatments for relapsed MM Update on related conditions (myeloma, AL amyloidosis etc) Speaker: Prof. Heinz Ludwig, Wilhelminen Cancer Research Institute, Austria
16:10 – 17:00	Spotlight on MPE scholarship programme Chair: Kate Morgan, MPE & Ana Vallejo, MPE Myeloma UK (UK) – Research Capacity Building Workshops, Jayne Galinsky Blodkreftforeningen (Norway) – Workshop on patient involvement in myeloma research, Jacob Hygen Kraujas (Lithuania) – Myeloma infoday and the book “Sexuality and oncological diseases”, Aistė Strelčiūnė Blodcancerförbundet Sweden (Sweden) – Workshop on combination therapy in myeloma, Lise-Lott Eriksson Borka (Macedonia) – Myeloma campaign “Let’s make changes”, Biba Dodeva
17:00 – 17:15	Coffee break
17:15 – 19:00	Plenary Workshop AL Amyloidosis Chair: Ananda Plate and Hans Scheurer, MPE Introduction to AL amyloidosis (20 min) Speaker: Dr Moshe Gatt, Israel AL amyloidosis from a patient advocates view (10 min.) Speaker: Daniel Drimer, Amyloidosis Israel Challenges of diagnosing myeloma from the patient advocates view (10 min.)Speaker: Varda Shoham, Myeloma Israel Workshop (40 min. team work in small groups and 20 minutes for discussion/feedback) How can the AL amyloidosis and myeloma community collaborate to help build a stronger AL amyloidosis community in Europe? What does the picture of diagnosing AL amyloidosis and myeloma look like in your country? How can we tackle the issue of late diagnosis of AL amyloidosis and myeloma at national level? What can MPE do to tackle the issue of late diagnosis of AL amyloidosis and myeloma at a Europe level?
20:00 – 22:00	Dinner (Hotel restaurant “Bistro”)

Saturday, 16 March 2019

09:00 – 10:00	Surrogate end-points and biomarkers in myeloma and AL amyloidosis Chair: Ron Dloomy, MPE Board Member Minimal residual disease in myeloma and AL amyloidosis Biomarkers in myeloma and AL amyloidosis Regulatory challenges associated with these and getting new medicines approved Speaker: Dr. Moshe Gatt, Israel
10:00 – 10:15	Coffee break
10:15 – 11:15	The role of CAR-T – Room: Sapporo/Harrare Chair: Roman Slomkowski, MPE Board Member What is CAR-T? How does it work? How is it being looked at in myeloma? Companies involved in this Application in AL amyloidosis? Regulatory challenges faced (e.g. cost, hospital provision etc) Role of advocacy in trying to make this available for patients Speaker: Dr. Michael Hudecek, University of Wuerzburg, Germany
11:15 – 11:30	Coffee break
11:30 – 12:30	AL amyloidosis clinical session – Updates in treatment of AL amyloidosis Chair: Lise-Lott Eriksson, Blodcancerförbundet Sweden Diagnostics Link between myeloma and AL amyloidosis Treatment of newly diagnosed AL amyloidosis (and updates from ASH) Treatment of relapse AL amyloidosis (and updates from ASH) Coordinated care in AL amyloidosis Upcoming treatments and clinical trials Speaker: Dr Moshe Gatt, Israel	Breakout Session Advocacy “Measuring and utilising quality of life” Chair: Kate Morgan, MPE PROMS, PREMS, PRO, QoL measures and patient Preference studies Examples in myeloma Examples in AL amyloidosis How they can be used in practice? Can they improve survival? Speaker: Jayne Galinsky, Myeloma UK
12:30 – 14:00	Lunch
14:00 – 16:15	ROTATING WORKSHOP SESSIONS (45 minutes each – Choose 2 out of 3, 15 min for rotation) Internal and external communications. How to create a communications strategy Speaker: Ana Vallejo, Myeloma Patients Europe Fundraising for patient groups Speaker: Michaela Geissler, Sarcoma Patients EuroNet Association (SPAEN) Reasonable Agreements between Patient Advocates and Pharmaceutical Companies Speaker: Jan Geissler, CML Advocates Network
16:15 – 16:45	Coffee Break
16:45 – 17:30	Supportive and psychosocial issues for myeloma and AL amyloidosis Chair: Ibolya Keri, MOHA, Hungary Psychosocial issues for patients (supportive care, emotional care etc) Speaker: Fatima Castaño, psycho-oncologist Communicating with patients Speaker: Diego Villalón, social worker, Fundación MÁS QUE IDEAS
19:30 – 22:00	Offsite dinner in Munich

Sunday, 17 March

8:30 – 10:45	General Assembly (for MPE members only)
11:15 – 11:450	Coffee break
11:45 – 13:00	General Assembly (for MPE members only)
13:00 – 14:00	Farewell lunch

For questions, please contact the MPE AGM team at agm@mpeurope.org

Web Links